Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies

The purpose of this study is to find out if an investigational treatment called, P-CD19CD20-ALLO1, is safe and will help treat people with one of the following B cell malignancies: diffuse large B cell lymphoma not otherwise specified (including diffuse large B cell lymphoma arising from indolent lymphomas), high-grade B Cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma or follicular lymphoma Grade 3B. The study is also being done to determine what dose is tolerated and to see if it is effective to treat the B cell malignancies listed above.